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Commentary
Pelvic inflammatory disease results from inflammation of the female upper genital tract and surrounding structures, most commonly from ascending infection. The disease affects 4% to 12% of young women and is a common cause of morbidity in this patient population. 7, 8 The presentation, signs, and symptoms vary and can be significant with complications. Consequently, the primary management includes broad-spectrum antibiotics that cover Chlamydia trachomatis, Neisseria gonorrhea, and anaerobic bacteria. [7] [8] [9] [10] [11] Despite several guidelines recommending addition of nitroimidazoles in pelvic inflammatory disease treatment, 7, 8 the authors found no difference in efficacy for treatment or adverse effects with the majority of comparisons performed using a nitroimidazole against a drug with anaerobic activity (eg, amoxacillinþclavulanate, clindamycin or ampicillinþsulbactam).
This meta-analysis includes trials from many different international populations of reproductive-age women. This study supports current antibiotic recommendations by the CDC for the treatment of all patients with pelvic inflammatory disease because all regimens studied demonstrated similar treatment efficacy and safety. 8 Only current CDC-recommended antibiotic regimens were included in this meta-analysis. The risk of bias in the included studies limits the conclusions. Among patients with mild to moderate pelvic inflammatory disease, azithromycin may have superior treatment efficacy compared with doxycycline. There is no clear evidence supporting addition of nitroimidazoles to other antibiotic regimens.
However, the meta-analysis included many trials at unclear or high risk of bias (only 3 studies at low risk of bias), and intention-to-treat analysis demonstrated substantial heterogeneity in results. Also, measurement bias is possible owing to investigator definition of cure because there is no widely accepted objective means of measuring this outcome. There is also a possibility of selection bias, given that pelvic inflammatory disease is a clinical diagnosis that is potentially subjective. 8 The literature would benefit from additional high-quality randomized controlled trials specifically comparing azithromycin with doxycycline for the treatment of mild to moderate pelvic inflammatory disease to confirm the superiority of azithromycin among this patient population, as detected by this meta-analysis as the treatment regimen with azithromycin is shorter and may result in improved compliance. 12 Such future trials should strive for objective definitions of pelvic inflammatory disease to achieve consistent inclusion criteria and objective definitions of cure to achieve consistent outcome measures. 
